ALERT:

Endometrial Cancer, Uterine Cancer Clinical Trial 20193007

[LCID Study Number: 20193007]

NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer

The purpose of this study is to compare any good and bad effects of using experimental study drugs cediranib alone, olaparib alone, or a combination of cediranib and olaparib.

Disease/Condition: Endometrial Cancer, Uterine Cancer

Department: Hematology and Oncology

Status: Active, Not Recruiting

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

Protocol #: 20193007
Principal Investigator(s): Corrine Zarwan
Trial Phase: Sponsor Initiated Study Phase 2